Early and Sustained Treatment Satisfaction Observed in Patients With Moderate to Severe Psoriasis Treated With Ixekizumab: Results From Second Interim Analysis of the Real-World Psoriasis in Special Areas (PSoSA) Study
Authors: Armstrong April , Lonowski Sarah , Fivenson David , Malatestinic William , Murage Mwangi James , Feely McDonald Meghan , Sheikhi Mehrabadi Ali , Merola Joseph F. 
Published: January 2025

Introduction: Psoriasis (PsO) is an inflammatory disease that affects 3.2% of the US adult population (1). Patients treated with biological agents show higher treatment satisfaction over those treated with oral therapy, phototherapy and topical therapy (1). Ixekizumab has proven to be effective in treating moderate-to-severe plaque PsO in clinical trials. This analysis describes treatment satisfaction with ixekizumab in a real-world population using the IDEOM-7 (International Dermatology Outcomes Measures) treatment satisfaction questionnaire (2).  
Methods: The Psoriasis in Special Areas (PSoSA) study is a US-based, 52-week (W), prospective, multicenter, single-arm, observational study that enrolled adults with moderate-to-severe plaque PsO and nail involvement, with/without scalp involvement, in patients who initiated ixekizumab. Here, we describe observed data from the second interim analysis of the PSoSA study. Treatment satisfaction is measured using DermStat-7 also referred as IDEOM-7, a 7-item questionnaire completed by patients to assess overall treatment satisfaction using a 5-point response option from 1 “not satisfied”, 2 “slightly satisfied”, 3 “somewhat satisfied”, 4 “mostly satisfied” to 5 “completely satisfied”. This questionnaire is a novel method for assessing effectiveness of treatment (3 items), convenience of treatment (3 items), and a single item assessing overall satisfaction. Patients were requested to complete the IDEOM-7 at each follow-up visit. Here we describe results from the 2nd interim analysis for patients with available data at W4, W12, and W24 based on responses to the questions. 
Results: At W4, 146 patients were analysed. 80.9% (n=106) of the patients treated with ixekizumab responded as “mostly or completely satisfied”, 11.5% (n=15) as “somewhat satisfied”, 6.1% (n=8) as “slightly satisfied” and 1.5% (n=2) as “not satisfied”. 
 At W12, 115 patients were analysed. 85.3% (n=93) of the patients treated with ixekizumab responded as “mostly or completely satisfied”, 7.3% (n=8) as “somewhat satisfied”, 3.7% (n=4) as “slightly satisfied” and 3.7% (n=4) as “not satisfied”. 
At W24, 71 patients were analysed. 86.4% (n=57) of the patients treated with ixekizumab responded as “mostly or completely satisfied”, 9.1% (n=6) as “somewhat satisfied”, 1.5% (n=1) as “slightly satisfied” and 3% (n=2) as “not satisfied”. 
Conclusion: In this second interim analysis of the PSoSA study, moderate to severe PsO patients initiating ixekizumab reported high levels of overall treatment satisfaction as early as week 4 which was sustained at week 24.  

Florek AG, Wang CJ, Armstrong AW. Treatment preferences and treatment satisfaction among psoriasis patients: a systematic review. Archives of Dermatological Research. 2018 May;310:271-319. 

Ball GD, Yee D, Zhang AJ, Perez-Chada LM, Strand V, Merola JF, Armstrong AW, Gottlieb AB. Report of the IDEOM meeting adjacent to the GRAPPA 2023 annual meeting. The Journal of Rheumatology. 2024 Jul 15.